Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Int+J+Infect+Dis 2020 ; 97 (ä): 7-10 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Lack of antiviral activity of darunavir against SARS-CoV-2 #MMPMID32479865
De Meyer S; Bojkova D; Cinatl J; Van Damme E; Buyck C; Van Loock M; Woodfall B; Ciesek S
Int J Infect Dis 2020[Aug]; 97 (ä): 7-10 PMID32479865show ga
OBJECTIVES: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. RESULTS: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC(50) > 100 muM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC(50) = 0.38 muM). CONCLUSIONS: Overall, the data do not support the use of DRV for the treatment of COVID-19.